newsfilter
← Latest News
PR Newswire·

Fusion Pharmaceuticals Announces Fourth Quarter 2022 Financial Results and Clinical Program Updates

Company recently acquired IND for ongoing Phase 2 clinical trial evaluating 225Ac-PSMA I&T, a small molecule radiopharmaceutical targeting PSMA positive mCRPC FPI-1434 preliminary Phase 1 data expected in Q2